AACR Annual Meeting 2026

NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer

NECTIN4, the target of enfortumab vedotin (EV), acts as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer. Integrating clinical multi-omics, spatial and single-cell immune profiling, and experimental models, the work shows NECTIN4-high basal/squamous muscle-invasive tumors had favorable survival, higher checkpoint inhibitor response rates, and a CD8+ T cell-inflamed microenvironment, with no comparable associations in luminal papillary tumors; NECTIN4-low models were preferentially sensitive to HDAC inhibition.

MSK research tech Abraham Meyerson’s poster about “Integrating padeliporfin vascular-targeted photodynamic therapy with enfortumab vedoti...

@jonchou05 delivers a tour de force presentation @AACR on resistance mechanisms to NECTIN4 therapy (enfortumab and CAR-T) in bladder canc...